Myelodysplastic Syndromes (MDS)

Sumithira Vasu, MD

Institution
Ohio State University Comprehensive Cancer Center
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About

I am a hematologist-oncologist who specializes in treating patients with acute myeloid leukemia (AML), myelodysplastic syndromes and bone marrow transplantation. Every day, I collaborate with my colleagues at the OSUCCC – James to create targeted therapies for each patient. Cancer is complex, but I’m confident our research continues to bring us closer to finding a cure. It’s an honor to work at one of the nation’s premier cancer hospitals. Our collective expertise results in faster responses, fewer side effects and more hope for cancer patients everywhere.

Cord Blood Transplant

Thumbnail for video Register Now

Topic(s)
Bone Marrow Transplant
Presenter(s)
Filippo Milano, MD, PhD
During this webinar, Dr. Filippo Milano will discuss cord blood transplant and its role in treating blood cancers and hematological disorders. He will discuss the unique benefits of cord blood as a stem cell source, recent advances in transplantation techniques, and strategies to…

Secondary Malignancies After Hematopoietic Stem Cell Transplantation

Original Publication Date
Article Source
External Web Content

Highlight The 10-year incidence of non-cutaneous SM (6.8%) confirms its impact on late NRM. SM subtype distribution and timing vary by transplant: t-MDS/AML after auto-HCT, PTLD early after allo-HCT. PTLD declined markedly, nearly disappearing in the PTCy era with less ATG/Cord…

Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis

Original Publication Date
Article Source
External Web Content

Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…

Outcomes of Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Over 70 Years of Age: A Comparative Analysis by Age Group

Original Publication Date
Article Source
External Web Content

Abstract Background We aimed to study outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients aged above 70 with using post-transplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD)…

Clonal Signatures of Telomere Biology Disorders

Original Publication Date
Article Source
External Web Content

Abstract Purpose of Review In inherited bone marrow failure syndromes (IBMFS), clonal hematopoiesis (CH) has been increasingly recognized as a molecular fingerprint of the underlying pathophysiology. A specific clonal profile has been reported in telomere biology disorders (TBDs)…

Patients with myelodysplastic/myeloproliferative neoplasms have higher rates of relapse following allogeneic hematopoietic cell transplantation compared to those with MDS: A Brazilian SBTMO/CIBMTR registry analysis

Original Publication Date
Article Source
External Web Content

Correspondence The Myelodysplastic/Myeloproliferative neoplasm (MDS/MPN) overlap syndromes are a heterogeneous group of rare hematologic malignancies characterized by features of both MDS such as morphologic dysplasia and cytopenias and MPNs including elevated blood counts and…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.